Kaynes Technology India (NSE:KAYNES) has an average rating of hold and mean price target of 3,932.67 Indian rupees, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Shenzhen Chipscreen Biosciences (SHA:688321) obtained the marketing approval of Macau's drug regulator for its chiglitazar sodium tablets.The drug, sold under the trade names Shuangluoping and Bilessglu, is indicated for type two diabetes as both monotherapy and in combination with metformin, according to a Friday filing with the Shanghai bourse.Shares of the drug developer closed 2% lower Friday.